Active Photocoagulated Diabetic Retinopathy, Proliferative Diabetic Retinopathy, Severe Nonproliferative
Conditions
Keywords
severe nonproliferative, proliferative diabetic retinopathy, active photocoagulated diabetic retinopathy, intravitreal bevacizumab
Brief summary
Background: to evaluate the 3-month efficacy of a single dose of intravitreal bevacizumab on the progression of severe non proliferative diabetic retinopathy, proliferative diabetic retinopathy and active photocoagulated diabetic proliferative by evaluation of ischemic areas and regression of retinal and disc neovasculrization. Methods: 40 patients were enrolled in a prospective, interventional study. Patients were treated with intravitreal bevacizumab 0.1ml (0.25mg). We evaluated visual acuity, neovascularization leakage points, capillary closure ischemic areas and macular edema by clinical examination and fluorescein angiography. A clinical examination was performed at baseline and days 1,14 and 30. Active leakage points were measured by fluorescein angiography at 30 days.
Interventions
Sponsors
Asociación para Evitar la Ceguera en México
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Severe nonproliferative * Proliferative diabetic retinopathy * Active photocoagulated diabetic retinopathy
Exclusion criteria
* Previous vascular occlusion * Glaucoma * Uncontrolled hypertension, thromboembolic event * Renal abnormalities * Recent or planned surgery * Coagulation abnormalities * Panretinal photocoagulation of less than one month before * Patients with known serious allergies
Countries
Mexico
Outcome results
None listed